Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antitumor Effects of Pan-RAF Inhibitor LY3009120 Against Lung Cancer Cells Harboring Oncogenic BRAF Mutation.

Anticancer research - 1 May 2020

Miyauchi Shunsaku, Shien Kazuhiko, Takeda Tatsuaki, Araki Kota, Nakata Kentaro, Miura Akihiro, Takahashi Yuta, Kurihara Eisuke, Ogoshi Yusuke, Namba Kei, Suzawa Ken, Yamamoto Hiromasa, Okazaki Mikio, Soh Junichi, Tomida Shuta, Yamane Masaomi, Sakaguchi Masakiyo, Toyooka Shinichi

Abstract excerpt

BACKGROUND/AIM: The therapeutic strategy for patients with non-small-cell lung cancer (NSCLC) harboring the BRAF non-V600E mutation has not been established. LY3009120, a newly discovered pan-RAF inhibitor, has shown strong antitumor effects in cancers with various BRAF genotypes. This study investigated the antitumor effects of LY3009120 in NSCLC cells harboring the BRAF non-V600E mutation. MATERIALS AND...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Inhibitory Concentration 50
Share to Mice, Inbred BALB C

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mice, Nude

Share to Oncogenes

Share to Phenylurea Compounds

Share to Proto-Oncogene Proteins B-raf

Share to Pyrimidines

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 32366411
DOI: 10.21873/anticanres.14237

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antitumor Effects of Pan-RAF Inhibitor LY3009120 Against Lung Cancer Cells Harboring Oncogenic BRAF Mutation.PMID 32366411Read ↗

Advances in anti-BRAF therapies for lung cancer.Semantic proximity Read ↗

SH003 Enhances the Anti-cancer Effects of Dabrafenib on Lung Cancer Harboring BRAF G469A Mutation by Inhibiting the MAPK Signaling Pathway.Semantic proximity Read ↗

Pathways and targeting avenues of BRAF in non-small cell lung cancer.Semantic proximity Read ↗

SH003 enhances the anti-cancer effects of Dabrafenib on lung cancer harboring BRAF G469A mutation by inhibiting the MAPK signaling pathwaySemantic proximity Read ↗

Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.Semantic proximity Read ↗

Evaluation of Pan-RAF Inhibitor LY3009120 on Human Uveal Melanoma Cell Line 92-1.Semantic proximity Read ↗

Combined blockade of polo-like kinase and pan-RAF is effective against NRAS-mutant non-small cell lung cancer cells.Semantic proximity Read ↗

Novel PI3K/Akt/mTOR pathway inhibitors plus radiotherapy: Strategy for non-small cell lung cancer with mutant RAS gene.Semantic proximity Read ↗

KPT-330 has antitumour activity against non-small cell lung cancer.Semantic proximity Read ↗

Antitumor Activity of a Novel Tyrosine Kinase Inhibitor AIU2001 Due to Abrogation of the DNA Damage Repair in Non-Small Cell Lung Cancer CellsSemantic proximity Read ↗

CDK4/6 inhibition stabilizes disease in patients with p16-null non-small cell lung cancer and is synergistic with mTOR inhibitionSemantic proximity Read ↗

Dual targeting of MEK and PI3K effectively controls the proliferation of human EGFR-TKI resistant non-small cell lung carcinoma cell lines with different genetic backgrounds.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.